{"version":"1.0","type":"link","title":"Predictive value of early PSMA upregulation for the response to enzalutamide ± Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial.","author_name":"Emmett L 외","author_url":"https://prs-insight.online/author/Emmett%20L","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/130634","thumbnail_width":1200,"thumbnail_height":630}